According to incomplete statistics from Innovation Radar, last week (August 11 to August 17), there were 16 disclosed financing events in the global healthcare sector, with a total amount exceeding 5.6 billion US dollars.

Small nucleic acid innovative drugs and delivery technologies continue to attract capital attention.Haichang Biotech Completes Nearly 500 Million Yuan in Series C FinancingThe company has established the proprietary QTsome technology platform in the field of drug delivery. Its core pipeline includes HC0301, a small nucleic acid innovative drug for primary liver cancer that has entered Phase 2 international multicenter clinical trials, and HC016 Lipid Complex Injection, a TLR9 immune agonist developed based on lipid nanoparticle delivery technology.

In addition to Haichang Biotech,Ribopeutic Announces Completion of Nearly 100 Million Yuan Pre-A Financing Round for Innovative Small Molecule Drug Development Targeting RNARibopeutic has established an AI-powered dry-wet closed-loop target discovery platform, which can effectively identify stable tertiary structures in RNA with potential small molecule binding pockets, precisely targeting "small molecule target sites" in RNA. Ribopeutic has also developed a targeted RNA small molecule screening, optimization, and validation technology platform, as well as a small molecule library specifically optimized for targeting stable tertiary structures of RNA. Currently, the company is advancing the development of pipelines in the fields of central nervous system disorders, cancer, and autoimmune diseases.

In the field of central nervous system,Jocasta Neuroscience Completes $35 Million Series A Financing to Advance Development of Its Core Product, a-Klotho Protein Compound JN-0413, and plans to submit an IND application in the fourth quarter of 2026. JN-0413 is dedicated to alleviating cognitive decline associated with neurodegenerative diseases, and its preliminary data indicate that the a-Klotho protein has shown potential in improving cognitive function in animal models.

Another American companySetPoint Medical Treats Chronic Immune Diseases Through Neuromodulation, Raising $140 Million in Series D and C Rounds, setting a record for the highest financing amount last week. In China,BCIFlex Secures Over 300 Million Yuan in Series A FinancingIts invasive flexible brain-computer interface technology reduces the proportion of brain occupancy and implantation damage, and has passed biocompatibility testing, with the potential to address unmet needs in the field of major diseases.

In addition,Cancer immunotherapy company NEX-I, cardiovascular medical device company Reprieve Cardiovascular, assisted reproductive technology company GametoAll have received financing.

Readers, please star ⭐Chuangjianhui to receive push notifications第一时间收到推送.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share with friends circle. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"InnoVantage"Contact us via WeChat Official Account comments.

More Data Content Recommendations

Click "InSee", Sharing New Health Trends from Chuangjian Hui